NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $4.04 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.03 -0.01 (-0.25%) As of 05/22/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About X4 Pharmaceuticals Stock (NASDAQ:XFOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get X4 Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.00▼$4.2050-Day Range$3.56▼$4.5052-Week Range$1.35▼$4.83Volume177,818 shsAverage Volume354,417 shsMarket Capitalization$381.05 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency. Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes. The company’s research and development pipeline also includes preclinical candidates exploring CXCR4 antagonism in inflammatory and fibrotic diseases. Headquartered in Bedford, Massachusetts, X4 Pharmaceuticals conducts global clinical studies across North America and Europe, leveraging collaborations with leading academic centers and regulatory bodies to support its development efforts. The company’s infrastructure emphasizes translational science, streamlined operations, and patient-centric trial design to accelerate the advancement of its programs. Publicly traded on the NASDAQ under the ticker XFOR, X4 Pharmaceuticals is dedicated to bringing innovative immunotherapeutics to underserved patient populations. Through strategic partnerships, regulatory engagement, and a focus on rare disease expertise, the company aims to deliver new treatment options that address significant unmet medical needs.AI Generated. May Contain Errors. Read More X4 Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreXFOR MarketRank™: X4 Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 601st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingX4 Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialX4 Pharmaceuticals has a consensus price target of $8.50, representing about 110.4% upside from its current price of $4.04.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.77) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.34% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 8.35.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 0.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.13% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XFOR Stock News HeadlinesHow The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU ProgressMay 21, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 25 at 1:00 AM | Paradigm Press (Ad)Guggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comSee More Headlines XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $4.00 on January 1st, 2026. Since then, XFOR shares have increased by 1.0% and is now trading at $4.04. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The firm had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million. X4 Pharmaceuticals had a negative trailing twelve-month return on equity of 94.90% and a negative net margin of 1,106.30%. When did X4 Pharmaceuticals' stock split? Shares of X4 Pharmaceuticals reverse split before market open on Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did X4 Pharmaceuticals IPO? X4 Pharmaceuticals (XFOR) raised $40 million in an IPO on Thursday, November 16th 2017. The company issued 4,000,000 shares at $10.00 per share. Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' top institutional shareholders include Stempoint Capital LP (0.90%), Bank of America Corp DE (0.16%), OMERS ADMINISTRATION Corp (0.06%) and SummitTX Capital L.P. (0.01%). Insiders that own company stock include Adam R Craig, Paula Ragan, Mark Baldry, Mary Dibiase, Arthur Taveras, Murray Stewart, Michael S Wyzga and Adam S Mostafa. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC). Company Calendar Last Earnings5/06/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 XFOR's financial health is in the Green zone, according to TradeSmith. XFOR has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XFOR CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees80Year Founded2010Price Target and Rating Average Price Target for X4 Pharmaceuticals$8.50 High Price Target$12.00 Low Price Target$3.50 Potential Upside/Downside+110.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.20 million Net Margins-1,106.30% Pretax Margin-1,106.22% Return on Equity-94.90% Return on Assets-48.09% Debt Debt-to-Equity Ratio0.45 Current Ratio10.18 Quick Ratio9.98 Sales & Book Value Annual Sales$35.11 million Price / Sales10.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book2.26Miscellaneous Outstanding Shares94,320,000Free Float93,254,000Market Cap$381.05 million OptionableNo Data Beta0.31 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:XFOR) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
